studi
aim
determin
profil
serum
cytokin
tnfa
chemokin
monocyt
chemoattract
rant
regul
activ
normal
cell
express
secret
individu
asthmat
versu
nonasthmat
background
bacteri
viral
mix
acut
respiratori
infect
asthmat
n
nonasthmat
n
patient
acut
viral
bacteri
mix
bacteri
virus
respiratori
infect
studi
patient
also
analys
individu
pneumonia
bronchiti
healthi
individu
similar
age
sex
n
use
control
cytokinechemokin
content
serum
determin
elisa
increas
cytokinechemokin
concentr
asthmat
nonasthmat
patient
observ
howev
higher
concentr
chemokin
rant
asthmat
patient
infect
virus
bacteria
bacteria
virus
mix
nonasthmat
patient
observ
gener
viral
mix
infect
better
cytokinechemokin
induc
bacteri
infect
cytokinechemokin
express
similarli
increas
asthmat
nonasthmat
patient
pneumonia
bronchiti
except
rant
remain
normal
level
bronchiti
circul
cytokin
profil
induc
acut
viral
bacteri
mix
lung
infect
relat
asthmat
background
except
chemokin
increas
asthmat
statu
respiratori
viral
bacteri
infect
profound
effect
asthma
viral
respiratori
infect
found
associ
asthma
exacerb
infect
associ
wheez
event
multipl
includ
respiratori
syncyti
viru
rsv
human
rhinoviru
metapneumoviru
parainfluenza
coronaviru
virus
well
typic
atyp
bacteria
previou
studi
shown
differ
bronchoalveolar
cytokin
profil
nonasthmat
asthmat
patient
sever
cytokin
describ
play
import
role
pathogenesi
asthma
tnfa
chemokin
monocyt
chemoattract
rant
regul
activ
normal
cell
express
secret
regard
tnfa
induc
proinflammatori
event
apoptosi
emphysema
lung
tissu
induc
releas
cytokin
chemokin
eosinophil
accumul
produc
neutrophil
inflamm
respiratori
disord
addit
induc
increas
product
increas
ige
product
involv
allerg
airway
inflamm
monocyt
chemoattract
rant
regul
activ
normal
cell
express
secret
import
leucocyt
recruit
lung
tissu
lung
inflammatori
event
howev
circul
cytokin
respons
viral
bacteri
respiratori
infect
asthmat
nonasthmat
statu
littl
studi
increas
circul
blood
level
sever
cytokin
viral
respiratori
tract
infect
report
cytokin
may
repres
inflammatori
marker
differ
profil
asthmat
nonasthmat
patient
addit
asthmat
background
infect
type
viral
bacteri
site
respiratori
infect
upper
lower
could
import
defin
circul
cytokin
profil
therefor
aim
studi
describ
chang
level
sever
inflammatori
tnfa
cytokin
chemokin
rant
system
circul
acut
viral
bacteri
infect
patient
asthmat
nonasthmat
background
relationship
respiratori
infect
site
upper
lower
patient
studi
popul
drawn
outpati
clinic
male
femal
patient
n
present
clinic
diagnosi
acut
respiratori
infect
ari
studi
tabl
inclus
criteria
individu
least
one
respiratori
symptom
cough
wheez
run
nose
sneez
suspect
profession
physician
respiratori
infect
patient
previou
diagnosi
asthma
accord
criteria
global
initi
asthma
gina
program
without
asthma
manifest
asthma
background
select
classifi
asthmat
patient
studi
n
patient
without
anteced
asthma
asthmat
background
classifi
nonasthmat
patient
n
patient
treat
antibiot
antiallerg
steroid
drug
blood
sampl
obtain
patient
asthmat
background
present
asthma
manifest
least
one
month
previou
moment
blood
sampl
obtain
suggest
clinic
xray
find
use
diagnosi
pneumonia
asthmat
n
nonasthmat
n
bronchiti
asthmat
n
nonasthmat
n
pneumonia
criteria
follow
temperatur
cough
without
sputum
hemoptysi
pleurit
chest
pain
myalgia
dyspnoea
fatigu
rale
rhonchi
wheez
bronchial
breath
sound
dull
percuss
gastrointestin
symptom
regard
chest
radiographi
presenc
pleural
effus
lobar
consolid
diffus
infiltr
observ
physic
examin
patient
present
acut
bronchiti
show
presenc
absenc
fever
tachypnea
cough
without
sputum
wheez
rhonchi
prolong
expir
evid
lung
consolid
absent
viral
presenc
studi
virus
asthmat
n
nonasthmat
n
bacteri
presenc
studi
bacteria
asthmat
n
nonasthmat
n
mix
presenc
studi
bacteria
virus
asthmat
n
nonasthmat
n
infect
confirm
presenc
agent
specimen
nasopharynx
bronchoalveolar
lavag
studi
perform
patient
obtain
patient
screen
patient
patient
confirm
presenc
studi
microorgan
type
sampl
select
healthi
individu
similar
age
year
sex
n
studi
control
control
individu
without
respiratori
symptom
evid
lung
radiographi
alter
neg
microorgan
result
bronchoscopi
nasal
sampl
exclud
individu
cardiac
diseas
immunodefici
chronic
inflammatori
diseas
addit
neg
studi
microorgan
normal
level
ige
normal
chest
radiographi
nonasthmat
background
blood
sampl
obtain
patient
time
specimen
nasopharynx
bronchoalveolar
obtain
serum
control
patient
store
use
work
carri
accord
code
ethic
world
medic
associ
declar
helsinki
experi
involv
human
ethic
committe
instituto
de
investigacion
cl
dr
erico
negrett
fonacit
caraca
venezuela
approv
studi
written
inform
consent
obtain
patient
control
prior
blood
collect
respiratori
viru
identif
viral
replic
demonstr
cell
cultur
protocol
nation
institut
health
usa
cell
grown
confluenc
eagl
minimum
essenti
medium
mem
contain
fb
antibioticantimycot
nasopharynx
bronchoalveolar
sampl
patient
sonic
centrifug
supernat
bacteri
speci
identifi
use
convent
bacteriolog
techniqu
presenc
serum
igg
antiatyp
bacteria
legionella
pneumophilla
coxiella
burnetti
chlamydia
trachomati
chlamydophila
pneumonia
micoplasma
pneumonia
determin
use
avail
commerci
kit
pneumoslid
igg
vircel
sl
granada
spain
quantif
serum
ige
b
tnfa
rant
b
tnfa
rant
content
measur
use
commerci
avail
elisa
kit
tnfa
diaclon
fleme
franc
endogen
rockford
il
usa
b
rant
alpco
diagnost
salem
nh
usa
result
express
pgml
serum
ige
content
determin
elisa
calbiochem
inc
san
diego
ca
usa
elisa
analys
perform
triplic
statist
analysi
valu
express
mean
ae
standard
deviat
data
analysi
perform
use
nonparametr
anova
kruskalw
test
dunn
multipl
comparison
test
twotail
p
valu
consid
statist
signific
increas
level
ige
asthmat
patient
n
compar
nonasthmat
patient
n
control
n
observ
asthmat
ae
nonasthmat
ae
control
ae
iuml
p
versu
control
nonasthmat
patient
respiratori
syncyti
viru
adenoviru
parainfluenza
influenza
studi
patient
identifi
asthmat
n
nonasthmat
n
sever
bacteria
found
streptococcu
pneumonia
escherichiacoli
klebsiella
pneumonia
pseudomona
aeruginosa
staphylococcu
aureu
hemolyt
group
beta
streptococcu
serratia
marcens
legionella
pneumophila
asthmat
n
nonasthmat
n
percentag
infect
patient
accord
asthmat
nonasthmat
statu
shown
tabl
gener
serum
level
tnfa
rant
patient
acut
respiratori
infect
found
increas
compar
healthi
control
cytokin
express
similar
asthmat
nonasthmat
patient
chemokin
rant
asthmat
patient
n
compar
control
n
nonasthmat
patient
n
significantli
increas
p
fig
subgroup
studi
accord
microorgan
type
infect
patient
infect
viru
asthmat
n
nonasthmat
n
mix
infect
bacterium
viru
asthmat
n
nonasthmat
n
show
increas
product
cytokin
asthmat
nonasthmat
patient
compar
control
asthmat
patient
show
elev
valu
chemokin
fig
bacteri
infect
induc
system
increment
cytokin
chemokin
asthmat
n
nonasthmat
n
patient
compar
healthi
control
howev
tnfa
rant
found
increas
asthmat
patient
fig
gener
valu
asthmat
nonasthmat
patient
ari
viral
mix
infect
better
cytokinechemokin
induc
bacteri
infect
fig
howev
similar
induc
effect
studi
infect
observ
fig
asthmat
nonasthmat
patient
pneumonia
asthmat
n
nonasthmat
n
fig
bronchiti
asthmat
n
nonasthmat
n
fig
show
increment
studi
cytokinechemokin
compar
healthi
control
howev
patient
asthmat
background
pneumonia
show
rant
level
increas
compar
control
nonasthmat
patient
fig
f
asthmat
patient
bronchiti
elev
level
rant
fig
f
asthma
complex
chronic
diseas
lung
incid
grow
age
complex
diseas
partli
due
environment
insult
allergen
microbi
infect
play
differenti
role
pathogenesi
microb
may
play
import
role
exacerb
asthma
determin
differenti
circul
cytokin
profil
could
relat
interact
asthmamicrob
asthmat
nonasthmat
patient
microbi
acut
respiratori
infect
studi
patient
without
asthmat
background
similar
system
cytokin
respons
microbi
acut
respiratori
infect
howev
asthmat
patient
signific
increment
chemokin
suggest
role
asthmat
background
differenti
respons
chemokin
import
recruit
tissu
local
immun
structur
cell
lung
relev
asthma
exacerb
studi
patient
asthmat
background
clinic
manifest
asthma
suggest
increas
level
chemokin
could
earli
manifest
asthma
exacerb
asthma
character
airway
inflamm
airway
wall
remodel
bronchial
hyperrespons
activ
helper
type
lymphocyt
eosinophil
figur
express
cytokinechemokin
serum
patient
acut
mix
viral
bacteri
respiratori
infect
increas
level
beta
tumour
necrosi
factoralpha
tnfa
interleukin
monocyt
chemoattract
regul
activ
normal
cell
express
secret
factor
rant
asthmat
nonasthmat
patient
observ
b
e
f
higher
level
nonasthmat
patient
observ
asthmat
patient
found
c
asthmat
n
nonasthmat
n
control
n
data
analys
use
nonparametr
anova
kruskalw
test
dunn
multipl
comparison
test
valu
express
mean
ae
standard
deviat
scandinavian
journal
immunolog
activ
mast
cell
characterist
featur
make
differ
atop
versu
nonatop
asthma
howev
proinflammatori
cytokin
respons
asthmat
nonasthmat
patient
lung
microbi
infect
similar
studi
suggest
system
proinflammatori
respons
common
aspect
lung
infect
sourc
increas
level
cytokinechemokin
patient
circul
lung
infect
could
involv
lung
tissu
andor
system
tissu
respiratori
tract
frequent
primari
site
microbi
infect
result
develop
acut
respiratori
distress
syndrom
lung
inflammatori
event
alveolar
compartment
could
lost
allow
passag
releas
cytokin
bloodstream
organ
pulmonari
endothelium
invers
lung
bloodstream
cytokin
tnfa
import
role
lung
dysfunct
studi
patient
microbi
lung
infect
increas
serum
level
proinflammatori
cytokin
tnfa
cytokin
chemokin
rant
suggest
complex
immun
interact
microbi
respiratori
infect
sourc
cytokin
may
cell
local
lung
tissu
regard
epitheli
cell
mast
cell
basophil
monocytemacrophag
lymphocyt
could
secret
divers
type
cytokin
chemokin
tnf
rant
lung
tissuemicrob
interact
howev
rule
role
cell
tissu
potenti
viral
pathogen
acut
respiratori
infect
includ
respiratori
syncyti
viru
rsv
human
rhinoviru
hrv
human
metapneumoviru
human
parainfluenza
viru
hpiv
human
bocaviru
influenza
virus
adenovirus
enteroviru
rsv
hrv
commonli
link
exacerb
asthma
well
pathogenesi
infect
parainfluenza
influenza
virus
gener
detect
asthma
exacerb
presenc
pathogen
rsv
adenoviru
hpiv
influenza
found
studi
howev
associ
clinic
manifest
asthma
patient
ari
accordingli
studi
serum
rsvinfect
patient
increas
level
tnfa
rant
similar
serum
cytokinechemokin
profil
observ
adenoviru
parainfluencia
viru
infect
viral
cytokinechemokin
induc
effect
probabl
common
featur
respiratori
viru
infect
addit
infect
rsv
could
risk
factor
lung
diseas
persist
cytokin
chemokin
fulli
recov
rsvinfect
patient
provid
substratum
develop
subsequ
asthma
recent
studi
begun
introduc
typic
bacteria
streptococcu
pneumonia
well
atyp
bacteria
chlamydia
pneumonia
respons
acut
wheez
children
streptococcu
pneumonia
main
pathogen
found
bacteri
infect
patient
bacterium
common
caus
pneumonia
world
risk
factor
weaken
protect
immun
pneumococcu
caus
seriou
diseas
grow
evid
indic
inflammasom
play
key
role
pathogenesi
acut
chronic
respiratori
diseas
inflammasom
activ
streptococcu
pneumonia
induc
chronic
inflamm
airway
patient
asthma
chronic
obstruct
pulmonari
diseas
could
mechan
induc
bacteri
cytokinechemokin
product
observ
studi
howev
cytokin
induc
bacteri
respiratori
infect
type
interferon
induc
viru
mix
infect
protect
streptococcu
pneumonia
infect
cytokinechemokin
respons
pattern
observ
studi
relat
microbi
infect
type
viral
bacteri
mix
howev
bacteri
infect
lower
cytokinechemokin
induc
effect
clear
explan
find
howev
report
bacteria
exert
differenti
effect
eosinophil
import
cell
respiratori
patholog
result
exacerb
inhibit
inflamm
lung
infect
patient
ari
infect
differ
bacteria
serum
valu
observ
bacteri
infect
patient
could
repres
result
respons
valu
found
mixedinfect
patient
viral
bacteri
n
mix
n
control
n
data
obtain
asthmat
nonasthmat
patient
data
analys
use
nonparametr
anova
kruskalw
test
dunn
multipl
comparison
test
valu
express
mean
ae
standard
deviat
bacteri
show
similar
valu
observ
viral
infect
suggest
higher
viral
cytokin
induc
effect
involv
cytokinechemokin
product
mix
infect
cytokinechemokin
harm
effect
lung
regardless
cytokin
product
sourc
studi
increas
express
tnfa
rant
serum
patient
viral
bacteri
respiratori
infect
could
involv
clinic
manifest
observ
patient
cytokin
could
deleteri
effect
lung
tissu
tnfa
induc
activ
sever
proinflammatori
event
apoptosi
lung
tissu
result
emphysema
induc
neutrophil
inflammatori
respons
respiratori
disord
releas
cytokin
chemokin
addit
induc
eosinophil
accumul
b
cell
growth
factor
properti
could
relat
activ
profil
observ
studi
shown
increas
product
cytokin
stimul
blymphocyt
produc
ige
increas
allerg
airway
inflamm
increas
level
circul
chemokin
found
asthmat
patient
could
reflect
lung
chemokin
product
may
import
leucocyt
recruit
lung
tissu
rant
involv
chemoattract
eosinophil
monocyt
tlymphocyt
therefor
high
relev
asthma
involv
recruit
regulatori
effector
leucocyt
monocyt
lymphocyt
basophil
tissu
therefor
chemokin
could
play
import
role
asthma
pathogenesi
ari
addit
increas
system
concentr
cytokin
chemokin
could
activ
circul
leucocyt
deleteri
effect
lung
increas
serum
concentr
ige
associ
increas
product
circul
found
patient
asthmat
background
suggest
possibl
role
ige
increas
level
cytokin
asthma
pathogenesi
regard
ige
role
allerg
inflamm
involv
figur
cytokinechemokin
product
asthmat
nonasthmat
patient
pneumonia
similar
increas
level
beta
tumour
necrosi
factoralpha
tnfa
interleukin
asthmat
nonasthmat
patient
observ
b
c
higher
level
monocyt
chemoattract
regul
activ
normal
cell
express
secret
factor
rant
asthmat
patient
found
e
f
asthmat
n
nonasthmat
n
control
n
data
analys
use
nonparametr
anova
kruskalw
test
dunn
multipl
comparison
test
valu
express
mean
ae
standard
deviat
basophil
mast
cell
degranul
activ
monocytemacrophag
stimul
cell
induc
local
infiltr
secret
amplifi
tissu
inflamm
previou
report
shown
differ
asthma
pulmonari
diseas
regard
cytokin
profil
bronchoalveolar
lavag
cytokin
profil
chronic
obstruct
pulmonari
diseas
copd
asthma
report
profil
cytokin
express
copd
differ
observ
asthma
infiltr
eosinophil
involv
product
usual
found
asthma
tnfa
play
promin
role
copd
studi
bronchoalveolar
lavag
cytokin
profil
analys
howev
circul
cytokin
profil
show
differ
express
proinflammatori
cytokin
profil
asthmat
nonasthmat
patient
suggest
similar
immun
respons
microbi
infect
high
level
chemokin
asthmat
patient
observ
suggest
increas
cellular
infiltr
monocyt
neutrophil
eosinophil
tissu
level
regard
role
chemokin
microbialassoci
asthma
exacerb
report
conclus
present
studi
demonstr
serum
cytokin
profil
asthmat
nonasthmat
patient
viral
andor
bacteri
respiratori
infect
similar
asthmat
statu
anatom
place
infect
bronchiti
pneumonia
relev
proinflammatori
cytokin
profil
except
high
valu
chemokin
observ
asthmat
patient
bacteri
viral
respiratori
infect
induc
differ
circul
cytokin
profil
howev
lower
cytokinechemokin
induc
effect
bacteri
infect
observ
precis
mechan
regard
effect
system
cytokin
drive
microbi
respiratori
infect
process
remain
elus
figur
cytokinechemokin
product
asthmat
nonasthmat
patient
bronchiti
increas
level
beta
tumour
necrosi
factoralpha
tnfa
interleukin
observ
remain
similar
asthmat
nonasthmat
patient
b
c
monocyt
chemoattract
asthmat
patient
found
increas
regul
activ
normal
cell
express
secret
factor
rant
found
similar
patient
compar
control
valu
e
f
asthmat
n
nonasthmat
n
control
n
data
analys
use
nonparametr
anova
kruskalw
test
dunn
multipl
comparison
test
valu
express
mean
ae
standard
deviat
